Kiniksa Pharmaceuticals Ltd

Stock Chart, Company Information, and Scan Results

$48.21(as of Mar 31, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Kiniksa Pharmaceuticals Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$48.21
Ticker SymbolKNSA
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees366
CountyUSA
Market Cap$3,497.7M

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Kiniksa Pharmaceuticals Ltd In Our Stock Scanner

As of Apr 01, 2026
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.